Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
206P - Isolated splenic metastasis from non-small cell lung cancer: Study of an extremely rare clinical entity with review of all cases reported in the literature (ID 515)
12:30 - 13:00 | Author(s): A. Giagounidis
Rarely, non-small cell lung cancer metastases have been reported in soft tissue, kidney, peritoneum, spleen, pancreas, intestine, bone marrow, eye, ovary, thyroid, heart, breast, nasal cavity and tonsils. As an isolated event, splenic metastasis from non-small cell lung cancer is exceedingly rare. Until now, only 29 cases have been reported in the medical literature.
We have reviewed the medical literature concerning this extremely rare clinical entity and we have found 29 cases. We have studied these cases concerning different parameters like age, gender, histology and side of primary lung lesion, time to splenic metastasis, symptoms of metastasis and treatment of primary tumour and treatment of splenic metastasis.
In these cases, was recorded a strong male predominance (58%), ranging in age from 49 to 82 (mean. 62,3 years). In most of the reports the primary tumor was located in the right lung. The most common histopathological subtype of lung cancer with isolated splenic metastasis was adenocarcinoma (44% of cases), following from the squamous cell cancer (17% of cases) and large cell lung cancer (17% of cases). Splenic metastasis was synchronous in 12 cases and metachronous in other 17 cases. In the 17 cases of metachronous isolated splenic metastasis the median interval between the diagnosis of primary tumor and isolated splenic metastasis was 22,2 months (range 2 to 96 months). The majority of cases were asymptomatic (62% of cases) and the diagnosis was serendipitously made at follow up exams. Some patients presented with splenic rupture (12% of cases), abdominal pain (21% of cases) and fever (3% of cases). The majority of patients underwent a surgical resection of the primary tumor (65% of cases). In the most cases, the patients underwent a splenectomy (83% of cases). The vast majority of patients died 1 to 49 months after splenectomy.
The appearance of this rare clinical entity ranges in age, symptoms and histological type of tumour. The management of this entity in the same way with an oligometastatic NSCLC (splenectomy), whenever feasible, seems to be the most appropriate treatment.
Clinical trial identification:
Legal entity responsible for the study:
Has not received any funding
All authors have declared no conflicts of interest.